Evidence map›Paper›PMID 41067858›Full record

ArticleTherapeutic advances in respiratory disease

Next-generation radiomic sequencing in non-small cell lung cancer: an alternative model to predict mutations from [18F]FDG PET/CT.

Lavinia Monaco, Cinzia Crivellaro, Elisabetta De Bernardi, Francesca Bono, Gabriele Casati, Davide Seminati, Diego Luigi Cortinovis, Federica Elisei, Vincenzo L'Imperio, Claudio Landoni and 4 more

Abstract read
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lavinia MonacoNuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.
Cinzia CrivellaroNuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.ORCID 0000-0002-2645-5236
Elisabetta De BernardiSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Francesca BonoSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Gabriele CasatiSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Davide SeminatiPathology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.
Diego Luigi CortinovisSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.ORCID 0000-0001-7611-7369
Federica EliseiNuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.
Vincenzo L'ImperioSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Claudio LandoniNuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Lombardy, Italy.ORCID 0000-0002-9199-1553
Fabio PagniSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Elia Anna TurollaSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Cristina MessaSchool of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Lombardy, Italy.
Luca GuerraNuclear Medicine Unit, Fondazione IRCCS San Gerardo dei Tintori, Via Cadore 48, Monza, Lombardy 20900, Italy.ORCID 0000-0003-4197-2060

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality worldwide. The introduction of targeted therapies against oncogenic drivers, particularly EGFR and KRAS mutations, has significantly improved patient outcomes. However, next-generation sequencing (NGS), the current gold standard for molecular profiling, is not always accessible in routine clinical practice, emphasizing the need for noninvasive surrogate biomarkers. Radiomics has emerged as a promising imaging-based approach that extracts a large number of quantitative features from standard modalities such as [18F]FDG PET/CT. By capturing tumor heterogeneity and biological characteristics, radiomics can provide clinically relevant insights and holds potential for identifying predictive biomarkers. Recent studies suggest that CT radiomic features related to heterogeneity, texture, and shape may predict EGFR and KRAS mutation status, while the integration of metabolic parameters from [18F]FDG PET radiomics may further enhance predictive performance and offer a more comprehensive characterization of tumor biology.

objectivesTo assess the putative role of [18F]FDG PET/CT radiomic features for the prediction of mutated NSCLC. STUDY

designThis retrospective observational study included patients with histologically confirmed NSCLC, molecularly profiled by NGS and who underwent baseline [18F]FDG PET/CT scans at Fondazione IRCCS San Gerardo dei Tintori, Monza. Tumor segmentation and radiomic feature extraction were performed on PET images using Pyradiomics, generating 766 quantitative features. Feature selection for EGFR and KRAS mutation association was conducted via repeated random subsampling and LASSO logistic regression. DATA SOURCE AND

methodsPatients' histological, clinical and PET/CT imaging data were obtained from the electronic clinical database and picture archiving and communication system of IRCCS Fondazione San Gerardo dei Tintori di Monza between January 2023 and December 2024. Data from 105 patients with biopsy-proven NSCLC and available NGS and [18F]FDG PET/CT scans were analyzed to identify radiomic features from PET images associated with specific mutations. Two different PET/CT scanners were used (Discovery IQ and Discovery MI, GE Healthcare), and radiomic features were extracted using IBSI-compliant algorithms, generating 766 features per tumor. Features correlated with mutations were selected using the Discovery MI dataset (55 patients) and subsequently evaluated on the independent Discovery IQ dataset (50 patients).

resultsNo radiomic features were identified as associated with EGFR mutation in the Discovery MI dataset. Among the features correlated with KRAS mutation in the Discovery MI dataset, FBS_glcm_MCC-a measure of image texture complexity-was confirmed to be associated with KRAS mutation in the independent Discovery IQ dataset, with an AUC of 0.68,

conclusionThe potential of [18F]FDG PET radiomics as a surrogate for genetic profiling in NSCLC is promising; however, these preliminary findings require further validation in larger cohorts.

Indexed as

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18High-Throughput Nucleotide SequencingLung NeoplasmsMutationPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAgedErbB ReceptorsFemaleHumansMaleMiddle AgedPredictive Value of TestsProto-Oncogene Proteins p21(ras)RadiomicsEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18KRAS protein, humanProto-Oncogene Proteins p21(ras)Radiopharmaceuticals[18F]FDG PET/CTEGFRKRASlung cancerNGSNSCLCradiomics

Identifiers

PMID41067858
PMCPMC12515289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.